Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label dose-escalation study of MDG1021 HA-1H TCR-modified T cells after allogeneic stem cell transplantation
NL-OMON55022Phase 1Completed
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Nov 2020
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MDG1021 in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), multiple myeloma (MM) and 6 more (4 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Incidence and severity of adverse events in dose-escalation, Maximum tolerated dose and/or recommended phase 2 dose and 1 more. Started Nov 2020; status: completed.
02
Drugs
MDG1021
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)multiple myeloma (MM)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON55022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55022.